Market Overview

A Preview Of Abaxis Q4 Earnings

Related ABAX
Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved
Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Abaxis (NASDAQ: ABAX) releases its next round of earnings Thursday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters guide for Thursday's Q4 earnings announcement after the bell.

Earnings and Revenue

Wall Street analysts see Abaxis reporting earnings of 31 cents per share on sales of $65.9 million.

If the company were to match the consensus estimate, earnings would be down 6.06 percent. Revenue would be up 13.33 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2018 Q2 2018 Q1 2018 Q4 2017
EPS Estimate 0.25 0.28 0.33 0.96
EPS Actual 0.31 0.34 0.28 0.33


Stock Performance

Over the last 52-week period, shares are up 44.79 percent. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. Analysts' have adjusted their estimates lower for EPS and revenues over the past 90 days. The average rating by analysts on Abaxis stock is a Sell. The validity of this rating has maintained conviction over the past 90 days.

Conference Call

Abaxis's Q4 conference call is scheduled to begin at 4:00 p.m. ET and can be accessed here.

Posted-In: Earnings News Previews Trading Ideas


Related Articles (ABAX)

View Comments and Join the Discussion!

Earnings Preview: Ethan Allen Interiors

Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings